8,168 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Burling Wealth Partners LLC

Burling Wealth Partners LLC bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,168 shares of the company's stock, valued at approximately $6,306,000. Eli Lilly and Company accounts for 1.3% of Burling Wealth Partners LLC's investment portfolio, making the stock its 16th largest holding.

A number of other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its holdings in Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the last quarter. Invst LLC boosted its stake in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock worth $4,918,000 after buying an additional 189 shares during the last quarter. McIlrath & Eck LLC grew its holdings in shares of Eli Lilly and Company by 3.4% in the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock valued at $426,000 after acquiring an additional 16 shares in the last quarter. Virtu Financial LLC increased its position in shares of Eli Lilly and Company by 111.7% in the third quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock valued at $5,786,000 after acquiring an additional 3,446 shares during the last quarter. Finally, SOA Wealth Advisors LLC. raised its holdings in Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company's stock worth $766,000 after acquiring an additional 20 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LLY shares. Guggenheim decreased their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday, April 14th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 price objective on the stock. Finally, Citigroup cut their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,017.00.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $830.57 on Thursday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $787.52 billion, a price-to-earnings ratio of 70.93, a P/E/G ratio of 1.40 and a beta of 0.51. The stock's fifty day moving average price is $826.81 and its two-hundred day moving average price is $819.07. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.